1. Evaluating the impact of missenses mutations in CYP2D6*7 and CYP2D6*14A: does it compromise tamoxifen metabolism?
- Author
-
Glauber M. Leitão, Danyelly Bg Martins, Renato P Melo-Neto, José L. Lima-Filho, Carlos Hm Castelletti, and Maria Acsm Borba
- Subjects
0301 basic medicine ,CYP2D6 ,Antineoplastic Agents, Hormonal ,Genotype ,In silico ,Mutation, Missense ,Breast Neoplasms ,Biology ,medicine.disease_cause ,Polymorphism, Single Nucleotide ,digestive system ,03 medical and health sciences ,0302 clinical medicine ,Catalytic Domain ,Genetics ,medicine ,Humans ,Allele ,skin and connective tissue diseases ,Alleles ,Pharmacology ,Mutation ,Tamoxifen ,030104 developmental biology ,Cytochrome P-450 CYP2D6 ,Protein destabilization ,030220 oncology & carcinogenesis ,Molecular Medicine ,Female ,Function (biology) ,medicine.drug - Abstract
CYP2D6 is a high polymorphic enzyme from P450, responsible for metabolizing almost 25% of drugs. The distribution of different mutations among CYP2D6 alleles has been associated with poor, intermediate, extensive and ultra-metabolizers. Aim: To evaluate how missenses mutations in CYP2D6*7 and CYP2D6*14A poor metabolizer alleles affect CYP2D6 stability and function. Materials & methods: CYPalleles database was used to collect polymorphisms data present in 105 alleles. We selected only poor metabolizers alleles that presented exclusively missenses mutations. They were analyzed through seven algorithms to predict the impact on CYP2D6 structure and function. Results: H324P, the unique mutation in CYP2D6*7, has high impact in enzyme function due to its occurrence between two alpha-helixes involved in active site dynamics. G169R, a mutation that occurs only in CYP2D6*14A, leads to the gain of solvent accessibility and severe protein destabilization. Conclusion: Our in silico analysis showed that missenses mutations in CYP2D6*7 and CYP2D6*14A cause CYP2D6 dysfunction.
- Published
- 2016